ClinicalTrials.gov
public full text
Public Domain
Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis
In a Phase 2 Simon's Optimal Two-Stages Design intravenous tocilizumab will be administered as single 8mg/Kg dose in patients affected by severe multifocal interstitial pneumonia correlated to SARS-CoV2 infection. Aim of the study is to test the hypothesis that an anti-IL6 treatment can be effective in calming the virus-induced cytokine storm, blocking deterioration of lung function or even promoting a rapid improvement of clinical conditions, preventing naso-tracheal intubation and/or death.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- COVID-19: Salvage TOcilizumab as a Rescue Measure#1088289
- Tocilizumab for Severe COVID-19 Infection and Multisystem Inflammatory Syndrome in Adults and Children#453441
- Tocilizumab in Coronavirus-19 Positive Patients#841197
- Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma#1057364
- Tocilizumab Treatment in Patients With COVID-19#801301
Record · ID 841015
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive